Daré Bioscience (NASDAQ:DARE) Receives Buy Rating from HC Wainwright

Daré Bioscience (NASDAQ:DARE)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research report issued on Wednesday, Benzinga reports. They presently have a $6.00 price target on the biotechnology company’s stock.

A number of other equities research analysts also recently weighed in on the company. Brookline Capital Management downgraded Daré Bioscience from a “buy” rating to a “hold” rating in a report on Wednesday, April 17th. Dawson James cut Daré Bioscience from a “buy” rating to a “neutral” rating in a research report on Tuesday, January 30th.

Daré Bioscience Stock Down 5.4 %

Shares of DARE opened at $0.31 on Wednesday. Daré Bioscience has a twelve month low of $0.27 and a twelve month high of $1.06. The company has a 50 day moving average of $0.45 and a 200-day moving average of $0.39. The stock has a market capitalization of $31.38 million, a P/E ratio of -0.92 and a beta of 1.31.

Daré Bioscience (NASDAQ:DARE) last announced its quarterly earnings results on Thursday, March 28th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.06. The business had revenue of $1.81 million for the quarter, compared to analyst estimates of $2.17 million. On average, sell-side analysts anticipate that Daré Bioscience will post -0.22 earnings per share for the current fiscal year.

Institutional Trading of Daré Bioscience

A hedge fund recently bought a new stake in Daré Bioscience stock. Armistice Capital LLC purchased a new position in shares of Daré Bioscience, Inc. (NASDAQ:DARE) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 6,470,000 shares of the biotechnology company’s stock, valued at approximately $2,988,000. Armistice Capital LLC owned 7.37% of Daré Bioscience as of its most recent filing with the Securities and Exchange Commission (SEC). 6.70% of the stock is owned by hedge funds and other institutional investors.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.